Companies Dominating the Tay-Sachs Disease Treatment Landscape
- Sio Gene Therapies Ltd.,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd,
- Pfizer Inc.,
- Bayer AG,
- Bausch Health Companies Inc.,
- Boehringer Ingelheim International GmbH,
- AbbVie Inc.,
- Amgen Inc.,
- Novartis AG
- Progenity, Inc.
There is no known cure for Tay-Sachs disease, but treatment is given for the symptoms, which can be different for different patients, and stages. The treatment approach can range from physical therapy, chest physiotherapy, and respiratory care, to antipsychotic medications, and other treatment methods. The major tay-sachs disease treatment market players manufacturing the various kind of drugs needed to treat the symptoms include
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of tay-sachs disease treatment is evaluated at USD 2.54 billion.
Tay-Sachs Disease Treatment Market size was over USD 2.42 billion in 2024 and is poised to exceed USD 4.97 billion by 2037, growing at over 5.7% CAGR during the forecast period i.e., between 2025-2037.
North America industry is estimated to account for largest revenue share by 2037, on the back of growing cases of Tay-Sachs disease in the region.
The major players in the market are Sio Gene Therapies Ltd, Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Amgen Inc. and others who manufacture drugs to treat the symptoms of Tay-Sachs disease.
